<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01096875</url>
  </required_header>
  <id_info>
    <org_study_id>UMT0043</org_study_id>
    <nct_id>NCT01096875</nct_id>
  </id_info>
  <brief_title>Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary Surgery</brief_title>
  <official_title>Assessment of the Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary ByPass Surgery; A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ankara University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Turkish Society of Hematology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ankara University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Experimental data have demonstrated favourable effects of statins on endothelial progenitor
      cell (EPC) mobilization from the bone marrow, and cardiac homing. The purpose of the present
      prospective randomized controlled trial is to determine the effects of aggressive
      atorvastatin treatment (40 mg daily 2-weeks prior to surgery) on the number of endothelial
      progenitor cells (EPCs) after cardiopulmonary bypass by comparing with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endothelial progenitor cells, a subgroup of hematopoietic stem cells have a significant role
      in vascular homeostasis. In animal models of ischemia, endothelial progenitor cells are
      rapidly incorporated into sites of neovascularization, have the potential to induce and
      augment vasculogenesis/ angiogenesis, prevent cardiomyocyte apoptosis in peri-infarct
      regions, and reduce adverse remodeling. Treatment with atorvastatin has been shown to
      increase endothelial progenitor cell count in patients with coronary artery disease.
      Therefore, we will investigate whether atorvastatin augments the number of endothelial
      progenitor cells after cardiopulmonary bypass in patients undergoing coronary artery bypass
      surgery (CABG). Thus, we conducted a randomized double-blind, placebo-controlled, 2-way
      parallel trial in 60 patients undergoing coronary artery bypass surgery. Patients will
      receive either 2-week treatment with atorvastatin or placebo prior to surgery. Endothelial
      progenitor cells will be quantitated by flow cytometric phenotyping obtained from peripheral
      blood samples. In addition, cardiac markers (CK-MB mass, cardiac troponin-I), biochemical
      profile, liver function tests, high sensitive C-reactive protein (hsCRP) and coagulation
      profile will be determined at 4 time points: 1) preoperatively (baseline); 2) 6 hours after
      the end of cardiopulmonary bypass; 3) 24 hours after surgery; 4) 5th days postoperatively.
      Clinical, operative characteristics, cardiac markers, high sensitive C-reactive protein and
      endothelial progenitor cell count will be compared between the groups. Adverse outcomes will
      also be noted and reported.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Progenitor Cells (EPCs) Count (Cells/Âµl)</measure>
    <time_frame>Postoperative 6th hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF %) Measured at 30 Days Postoperatively</measure>
    <time_frame>Change between statin and placebo groups at 30 days postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Sensitive C-reactive Protein (hsCRP mg/L)</measure>
    <time_frame>Postoperative 6th hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Sensitive C-reactive Protein (hsCRP mg/L)</measure>
    <time_frame>5 days postoperatively</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Coronary Artery Bypass Surgery</condition>
  <condition>Elective Surgical Procedure</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxymethylglutaryl-CoA Reductase Inhibitors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Atorvastatin like pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>40mg/day once daily for two weeks prior to surgery</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Ator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1tb/day once daily for two weeks prior to surgery</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo tablets matched to atorvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing elective isolated coronary artery bypass surgery with on-pump
             technique

          -  Written informed consent

        Exclusion Criteria:

          -  Concomitant valve or aortic surgery

          -  Left ventricular aneurysm repair

          -  Re-operation

          -  Emergency surgery

          -  History of myocardial infarction within less than 4 weeks

          -  Hepatic impairment

          -  Chronic renal impairment

          -  Drug related side effects (allergy or hypersensitivity)

          -  Familial Hyperlipidemia

          -  Autoimmune conditions which require steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RUCHAN AKAR, Assoc. Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Ankara University Medical Faculty, Department of Cardiovascular Surgery Ankara, Turkey, 06340</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ONDER ASLAN, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Ankara University Medical Faculty, Department of Hematology Ankara, Turkey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ankara University Medical Faculty, Department of Cardiovascular Surgery</name>
      <address>
        <city>Ankara</city>
        <state>Cebeci</state>
        <zip>06340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2010</study_first_posted>
  <results_first_submitted>February 10, 2013</results_first_submitted>
  <results_first_submitted_qc>July 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2014</results_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ankara University</investigator_affiliation>
    <investigator_full_name>A. Ruchan Akar</investigator_full_name>
    <investigator_title>Professor, Consultant Cardiovascular Surgeon</investigator_title>
  </responsible_party>
  <keyword>Endothelial progenitor cells</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Coronary surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin</title>
          <description>Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atorvastatin : 40mg/day once daily for two weeks prior to surgery</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Atorvastatin like pill
Placebo : 1tb/day once daily for two weeks prior to surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin</title>
          <description>Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atorvastatin : 40mg/day once daily for two weeks prior to surgery</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Atorvastatin like pill
Placebo : 1tb/day once daily for two weeks prior to surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.8" spread="8.6"/>
                    <measurement group_id="B2" value="62.2" spread="8.1"/>
                    <measurement group_id="B3" value="61.6" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endothelial Progenitor Cells (EPCs) Count (Cells/Âµl)</title>
        <time_frame>Postoperative 6th hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atorvastatin : 40mg/day once daily for two weeks prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Atorvastatin like pill
Placebo : 1tb/day once daily for two weeks prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Progenitor Cells (EPCs) Count (Cells/Âµl)</title>
          <units>cells/Âµl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="0.06"/>
                    <measurement group_id="O2" value="2.19" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Ejection Fraction (LVEF %) Measured at 30 Days Postoperatively</title>
        <time_frame>Change between statin and placebo groups at 30 days postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atorvastatin : 40mg/day once daily for two weeks prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Atorvastatin like pill
Placebo : 1tb/day once daily for two weeks prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF %) Measured at 30 Days Postoperatively</title>
          <units>percentage of LVEF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" spread="7.5"/>
                    <measurement group_id="O2" value="53.2" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Sensitive C-reactive Protein (hsCRP mg/L)</title>
        <time_frame>Postoperative 6th hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atorvastatin: 40mg/day once daily for two weeks prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Atorvastatin like pill
Placebo: 1tb/day once daily for two weeks prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>High Sensitive C-reactive Protein (hsCRP mg/L)</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" spread="0.6"/>
                    <measurement group_id="O2" value="96.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Sensitive C-reactive Protein (hsCRP mg/L)</title>
        <time_frame>5 days postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atorvastatin: 40mg/day once daily for two weeks prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Atorvastatin like pill
Placebo: 1tb/day once daily for two weeks prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>High Sensitive C-reactive Protein (hsCRP mg/L)</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.2"/>
                    <measurement group_id="O2" value="11.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days postoperatively</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin</title>
          <description>Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atorvastatin : 40mg/day once daily for two weeks prior to surgery</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Atorvastatin like pill
Placebo : 1tb/day once daily for two weeks prior to surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Low cardiac output</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The major limitation of this study is lack of functional assessment of EPCs using in vitro analysis of colony forming units because of the financial constraints.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof. A. Ruchan Akar MD., FRCS(CTh).</name_or_title>
      <organization>Ankara University Medical Faculty, Department of Cardiovascular Surgery</organization>
      <phone>+90 533 646 06 84</phone>
      <email>akarruchan@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

